Ultrasound microbubble contrast and current clinical applications

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 1, 2011, Pages 27-41

  Dindya, Shiva ^a   Kyriakides, Constantinos ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Clinical; Contrast; Microbubble; Ultrasound

Indexed keywords

ALBUNEX; ECHO CONTRAST MEDIUM; ECHOVIST; PERFLUTREN; SHU 508; SONOVUE; SULFUR HEXAFLUORIDE;

ABDOMINAL BLUNT TRAUMA; ADNEXA DISEASE; ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; BILE DUCT DISEASE; BREAST CARCINOMA; BURNING SENSATION; CHRONIC TOXICITY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED ULTRASOUND; CONTRAST ENHANCEMENT; DRUG COST; DRUG ELIMINATION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ECHOCARDIOGRAPHY; GALLBLADDER CARCINOMA; GENOTOXICITY; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYDROURETER; INJECTION SITE CONTUSION; INJECTION SITE PAIN; KIDNEY ARTERY STENOSIS; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MICROBUBBLE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; OVARY CARCINOMA; OVARY CYST; PANCREAS CARCINOMA; PARESTHESIA; PRIORITY JOURNAL; PROSTATE CANCER; REPRODUCTIVE TOXICITY; RHEUMATOID ARTHRITIS; SPLEEN INJURY; STENT; STROKE; SYNCOPE; TESTIS TORSION; TISSUE DOPPLER IMAGING; TRANSRECTAL ULTRASONOGRAPHY; TRANSVAGINAL ECHOGRAPHY; ULTRASOUND; UNSPECIFIED SIDE EFFECT; VESICOURETERAL REFLUX;

ANIMALS; CONTRAST MEDIA; HUMANS; MICROBUBBLES; PHOSPHOLIPIDS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SULFUR HEXAFLUORIDE; ULTRASONOGRAPHY;

EID: 79551668706     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489011794578446     Document Type: Article

References (279)

1. Gramiak R, Shah PM, Kramer DH. Ultrasound cardiography: Contrast studies in anatomy and function. Radiology 1969; 92: 939-948.
2. Gramiak R, Shah PM. Echocardiography of the aortic root. Invest Radiol 1968; 3: 356-366.
3. Feinstein SB, Coll B, Staub D, Adam D, Schinkel AFL, Cate FJt, et al. Contrast enhanced ultrasound imaging. J Nucl Cardiol 2009; 17 (1): 106-115.
4. Tinkov S, Bekeredijan R, Winter G, Coester C. Microbubbles as ultrasound triggered drug carriers. J Pharm Sci 2009; 98 (6): 1935-1961.
5. Blomley M, Cosgrove D. Microbubble echo-enhancers: A new direction for ultrasound? Lancet 1997; 349: 1855-1856.
6. Fritzsch T, Neye H. Preliminary results with a new liver specific ultrasound contrast agent. Ultrasound Med Biol 1994; 20: 137.
7. Becher H, Zähler K, Grube E, Schlief R, Lüderitz B. Improving color Doppler echocardiography of the right heart chambers following intravenous injection of SHU 454. Erratum Z Kardiol 1988; 77 (6): 398.
8. Kremkau FW, Shah PM, Kramer DH. Ultrasonic detection of cavitation at catheter tips. Am J Roentgenol Radium Ther Nucl Med 1970; 110 (1): 177-183.
9. Leen E, Moug SJ, Horgan P. Potential impact and utilization of ultrasound contrast media. Eur Radiol 2004; 14(Suppl 8): P16-P24.
10. Piscaglia F, Bolondi L. The safety of Sonovue in abdominal applications: Retrospective analysis of 23188 investigations. Ultrasound Med Biol 2006; 32: 1369-1375.
11. Jackobsen J, Oyen R, Thomsen H, Morcos S. Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Safety of ultrasound contrast agents. Eur Radiol 2005; 5: 941-945.
12. Feinstein SB. The powerful microbubble: From bench to bedside, from intravascular indicator to therapeutic delivery system, and beyond. Am J Physiol Heart Circ Physiol 2004; 287: H450-H457.
13. Granada JF, Feinstein SB. Imaging of the vasa vasorum. Nat Clin Pract Cardiovasc Med 2008; 5: S18-S25.
14. Cosgrove D. Future prospects for SonoVue and CPS. Eur Radiol Suppl 2004; 14 (Suppl 8): P116-P124.
15. Bauer A, Solbiati L. Ultrasound contrast agents. In: Solbiati L, Ed. Contrast-Enhanced Ultrasound of Liver Diseases. Milan: Springer 2003: 21-26.
16. Burns P. Contrast ultrasound technology. In: Solbiati L, ed. Contrast-Enhanced Ultrasound of Liver Diseases. Milan: Springer 2003: 1-18.
17. Correas JM, Bridal L, Lesavre A, Méjean A, Claudon M, Hélénon O. Ultrasound contrast agents: Properties, principles of action, tolerance, and artifacts. Eur Radiol 2001; 11: 1316-1328.
18. Nihoyannopoulis P. Contrast echocardiography. Clin Radiol 1996; 51(Suppl 1): 28-30.
19. Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D, Pirenne J, Nevens F, et al. Focal lesions in cirrhotic explants livers: Pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002; 9: 762-764.
20. Cosgrove D. Ultrasound contrast agents: an overview. Eur J Radiol 2006; 60 (3): 324-330.
21. Averkiou M, Powers J, Skyba D, Bruce M, Jensen S. Ultrasound contrast imaging research. Ultrasound Q 2003; 19: 27-37.
22. Simpson DH, Chin CT, Burns PN. Pulse inversion Doppler: A new method for detecting nonlinear echoes from microbubble contrast agents. IEEE Trans Ultrasonics, Ferroelectrics Freq Control 1999; 46: 372-382.
23. Burns P, Powers J, Simpson HD, Uhlendorf V, Fritzsch T. Harmonic Imaging: Principles and preliminary results. Angiology 1996; 47: S63-S74.
24. Schrope BA, Newhouse VL. Second harmonic ultrasonic blood perfusion measurement. Ultrasound Med Biol 1993; 19: 567-579.
25. EFSUMB Study Group, Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F, et al. Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) - Update 2008. Ultraschall Med 2008; 29: 28-44.
26. Tiemann K, Lohmeier S, Kuntz S, Köster J, Pohl C, Burns P, et al. Real-Time contrast echo assessment of myocardial perfusion at low emission power: First experimental and clinical results using power pulse inversion imaging. Echocardiography 1999; 16: 799-809.
27. Villarraga HR, Foley DA, Aeschbacher BC, Klarich KW, Mulvagh SL. Destruction of contrast microbubbles during ultrasound imaging at conventional power output. J Am Soc Echocardiogr 1997; 10(8): 783-791.
28. Walker KW, Pantely GA, Sahn DA. Ultrasound-mediated destruction of contrast agents. Effect of ultrasound intensity, exposure, and frequency. Invest Radiol 1997; 32(12): 728-734.
29. Tinkov S, Bekeredjian R, Winter G, Coester C. Microbubbles as ultrasound triggered drug carriers. J Pharm Sci 2009; 98(6): 1935-1961.
30. Lim AK, Patel N, Eckersley RJ, Taylor-Robinson SD, Cosgrove DO, Blomley MJ. Evidence for spleen-specific uptake of a microbubble contrast agent: A quantitative study in healthy volunteers. Radiology 2004; 23: 785-788.
31. Schneider M. Characteristics of SonoVue. Echocardiography 1999; 16(7) Part 2: 743-746.
32. Lindner JR. Microbubbles in medical imaging: Current applications and future directions. Nat Rev Drug Discov 2004; 3: 527-532.
33. Schlief R. Galactose based echo-enhancing agents. In: Goldberg BG, Ed. Ultrasound contrast agents. London: Martin Dunitz 1997: 75-82.
34. Pitt WG, Husseini GA, Staples BJ. Expert opinion on ultrasound drug delivery-A general review. Expert Opin Drug Deliv 2004; 1: 37-56.
35. Shohet RV, Chen S, Zhou YT, Wang Z, Meidell RS, Unger RH, et al. Echocardiographic destruction of albumin microbubbles directs gene delivery through microbubbles. Prog Cardiovasc Dis 2001; 44: 45-54.
36. Unger EC, Hersh E, Vannan M, Matsunaga TO, McCreery T. Local drug and gene delivery through microbubbles. Prog Cardiovasc Dis 2001; 44: 45-54.
37. Ishihara K. Ultrasonic control of drug releasing. Jpn J Artif Organs 1984; 13: 1205-1208.
38. Bernatik T, Becker D, Neureiter D, Hänsler J, Frieser M, Schaber S, et al. Detection of liver metastases - comparison of contrast - enhanced ultrasound using first versus second generation contrast agents. Ultraschall Med 2003; 24: 175-179.
39. Leen E, Horgan P. Ultrasound contrast agents for hepatic imaging with non-linear modes. Curr Probl Diagn Radiol 2003; 32: 66-87.
40. Basilico R, Blomley MJ, Harvey CJ, Antonella F, Rolf AH, Robert JE, et al. Which continuous US scanning mode is optimal for the detection of vascularity in liver lesions when enhanced with a second generation contrast agent? Eur J Radiol 2002; 41: 184-191.
41. Schneider M. Design of an ultrasound contrast agent for myocardial perfusion. Echocardiography 2000; 17(6) Part 2: S11-16.
42. Schneider M, Arditi M, Barrau M, Brochot J, Broillet A, Ventrone R, et al. BR1: A new ultrasonographic contrast agent based on sulfur hexafluoride-filled microbubbles. Invest Radiol 1995; 30: 451-457.
43. Greis C. Technology overview: SonoVue (Bracc, Milan). Eur Radiol 2004; 14 (Suppl 8): 11-15.
44. Spinazzi A. Emerging clinical applications for contrast-enhanced ultrasonography. Eur Radiol 2001; 11(Suppl 3): E7-12.
45. Morel DR, Schwieger I, Hohn L, Terrettaz J, Llull JB, Cornioley YA, et al. Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol 2000; 35: 80-85.
46. Bokor D, Chambers J, Rees P, Mant TG, Luzzani F, Spinazzi A. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease. Invest Radiol 2001; 36: 104-109.
47. Bracco. SonoVue. Summary of product characteristics. 2005.
48. Jung P, Rieber J, Sohn HJ, Hoyer C, Erhardt I, Nowotny A, et al. Safety of first- and second-time application of transpulmonary ultrasound contrast agents during stress echocardiography. Eur J Echocardiogr 2007; 8 (Suppl 1): 707.
49. Timperley J, Mitchell AR, Thibault H, Mirza IH, Becher H. Safety of contrast dobutamine stress echocardiography: A single center experience. J Am Soc Echocardogr 2005; 18(2): 163-167.
50. Barnett SB, Duck F, Ziskin M. Recommendations on the safe use of ultrasound contrast agents. Ultrasound Med Biol 2007; 33: 173-174.
51. Blomley M, Claudon M, Cosgrove D. WFUMB Safety Symposium on Ultrasound Contrast Agents: Clinical Applications And Safety Concerns. Ultrasound Med Biol 2007; 33: 180-186.
52. Vancraeynest D, Kefer J, Hanet C, Fillee C, Beauloye C, Pasquet A. Release of cardiac bio-markers during high mechanical index contrast-enhanced echocardiography in humans. Eur Heart J 2007; 28: 1236-1241.
53. Jungehulsing GJ, Brunecker P, Nolte CH, Fiebach JB, Kunze C, Doepp F, et al. Diagnostic transcranial ultrasound perfusionimaging at 2.5MHz does not affect the blood-brain barrier. Ultrasound Med Biol 2008; 34 (1): 147-150.
54. Cosyns B, Weytjens C, Vanderhoogstrate M, Daniels C, Schoors D, Van Camp G, et al. Tissue Doppler imaging does not show infraclinical alteration of myocardial function after contrast echocardiography. Eur J Echocardiogr 2005; 6 (4): 238-242.
55. Education and Practical Standards Committee, European Federation of Societies for Ultrasound in Medicine and Biology. Minimum Training Recommendations For The Practice Of Medical Ultrasound. Ultraschall Med 2006l 27: 79-105.
56. EFSUMB Study Group. Guidelines for the use of contrast agents in ultrasound. Ultraschall Med 2004; 25 (4): 249-256.
57. Xiaoyan X, Guang H, Feng X, et al. Focal liver lesions ultrasound contrast: The light of the European Clinical Guide. China Ultrasound Image Mag 2006; 06: 1-16.
58. Tranquart F, Claudon M, Correas JM. Guidelines for the use of contrast agents in ultrasound. J Radiol 2005; 86: 1047-1054.
59. Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL, et al. Contrast echocardiography: Evidencebased recommendations by European Association of Echocardiography. Eur J Echocardiogr 2009; 10: 194-212.
60. Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, et al. American Society of Echocardiography Consensus Statement on the Clinical Applications Of Ultrasonic Contrast Agents In Echocardiography. J Am Soc Echocardiogr 2008; 21: 1179-11201 quiz 1281.
61. Mulvagh SL, DeMaria AN, Feinstein SB, Burns PN, Kaul S, Miller JG, et al. Contrast echocardiography: Current and future applications. J Am Soc Echocardiogr 2000; 13: 331-342.
62. Yong Y, Wu D, Fernandes V, Shimoni S, Nagueh SF, Callahan JD, et al. Diagnostic accuracy and cost-effectiveness of contrast echocardiography on evaluation of cardiac function in technically very difficult patients in intensive care unit patients. J Am Coll Cardiol 2002; 89: 711-718.
63. Daniel C. Echocardiographic imaging of technically difficult patients in the ICU. J Am Soc Echocardiogr 2001; 14: 917-920.
64. Reilly JP, Tunick PA, Timmermans RJ, Stein B, Rosenzweig BP, Kronzon I. Contrast echocardiography clarifies uninterpretable wall motion in intensive care patients. J Am Coll Cardiol 2000; 35: 485-490.
65. Kurt M, Shaikh KA, Peterson L, Kurrelmeyer KM, Shah G, Nagueh SF, et al. Impact of contrast echocardiography on evolution of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol 2009; 53: 802-810.
66. Kono Y, Pinell SP, Sirlin CB, Sparks SR, Georgy B, Wong W, et al. Carotid arteries: Contrast enhanced US angiographypreliminary clinical experience. Radiology 2004; 230: 561-568.
67. Mattrey RF, Kono Y. Contrast-specific imaging and potential vascular applications. Eur Radiol 1999; 9: S353-S358.
68. Doyle B, Caplice N. Plaque neovascularization and atherogenic therapy for atherosclerosis. J Am Coll Cardiol 2007; 49 (21): 2073-2080.
69. Geiringer E. Intimal vascularization and atherosclerosis. J Pathol Bacteriol 1951; 63 (2): 201-211.
70. Xiong L, Deng YB, Zhu Y, Liu YN, Bi XJ. Correlation of carotid plaque neovascularization detected by using contrast-enhanced US with clinical symptoms. Radiology 2009; 251: 583-589.
71. Coli S, Magnoni M, Sangiorgi G, Marrocco-Trischitta MM, Melisurgo G, Mauriello A, et al. Contrast-enhanced ultrasound imaging of intraplaque neovascularization in carotid arteries: Correlation with histology and plaque echogenicity. J Am Coll Cardiol 2008; 52: 223-230.
72. Feinstein SB. Contrast ultrasound imaging of the carotid artery vasa vasorum and atherosclerotic plaque neovascularization. J Am Coll Cardiol 2006; 48: 236-243.
73. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7 (4): 425-429.
74. Fleiner M, Kummer M, Mirlacher M, Sauter G, Cathomas G, Krapf R, et al. Arterial neovascularization and inflammation in vulnerable patients: Early and late signs of symptomatic atherosclerosis. Circulation 2004; 110 (18): 2843-2850.
75. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: Implications for plaque vulnerability. Circulation 2004; 110(14): 2032-2038.
76. Chen YX, Nakashima Y, Tanaka K, Shiraiahi S, Nakagawa K, Sueishi K. Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries. Arterioscler Thromb Vasc Biol 1999; 19 (1): 131-139.
77. de Boer OJ, van der Wal AC, Teeling P, Becker AE. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: A prominent role for neovascularization? Cardiovasc Res 1999; 41 (2): 443-449.
78. McCarthy MJ, Loftus IM, Thompson MM, Jones L, London NJ, Bell PR, et al. Angiogenesis and the atherosclerotic carotid plaque: An association between symptomatology and plaque morphology. J Vasc Surg 1999; 30(2): 261-268.
79. Heliopoulos I, Papazoglou D, Piperidou H, Vadikolias K, Maltezos E, Artemis N. Carotid plaque echomorphology and serum vascular endothelial growth factor levels. Eur Neurol 2004; 51: 104-108.
80. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
81. Coll B, Feinstein SB. Carotid intima-media thickness measurements: Techniques and clinical relevance. Curr Atheroscler Rep 2008; 10: 444-450.
82. Chugh A, Patel SN, Rajaram V, Neems R, Feinstein M, Goldin M, et al. The Clinical Use of Non-Invasive Modalities in the Assessment of Atherosclerosis. chap 18. In: Davidson M, Toth P, Maki K, Eds. Therapeutic Lipidology. Humana Press: USA 2007; 389-408.
83. Macioch JE, Katsamakis CD, Robin J, Liebson PR, Meyer PM, Geohas C, et al. Effects of contrast enhancement on measurement of carotid artery intimal medial thickness. Vasc Med 2004; 9: 7-12.
84. Shah F, Balan P, Weinberg M, Reddy V, Neems R, Feinstein M, et al. Contrast-enhanced ultrasound imaging of atherosclerotic carotid plaque neovascularization: A new surrogate marker of atherosclerosis? Vasc Med 2007; 12: 291-297.
85. Clevert DA, Minaifar N, Weckbach S, Kopp R, Meimarakis G, Clevert DA, et al. Color duplex ultrasound and contrast-enhanced ultrasound in comparison to MS-CT in the detection of endoleak following endovascular aneurysm repair. Clin Hemorheol Microcirc 2008; 39: 121-132.
86. Shalhoub J, Owen DRJ, Gauthier T, Monaco C, Leen ELS, Davies AH. The use of contrast enhanced ultrasound in carotid arterial disease. Eur J Vasc Endovasc Surg 2010; 39: 381-387.
87. Nabavi DG, Droste DW, Kemeny V, Schulte-Altedorneburg G, Weber S, Ringelstein EB. Potential and limitations of echocontrast-enhanced ultrasonography in acute stroke patients: A pilot study. Stroke 1998; 29(5): 949-954.
88. Baumgartner RW, Arnold M, Gonner F, Staikow I, Herrmann C, Rivoir A, et al. Contrast-enhanced trans-cranial colour-coded duplex sonography in ischemic cerebrovascular disease. Stroke 1997; 28 (12): 2473-2478.
89. Postert T, Federlein J, Przuntek H, Buttner T. Insufficient and absent acoustic temporal bone window: Potential and limitations of trans-cranial contrast-enhanced colour-coded sonography and contrast-enhanced power-based sonography. Ultrasound Med Biol 1997; 23 (6): 857-862.
90. Gerriets T, Goertler M, Stolz E, Postert T, Sliwka U, Schlachetzki F, et al. Feasibility and validity of trans-cranial duplex sonography in patients with acute stroke. J Neurol Neurosurg Psychiatry 2002; 73 (1): 17-20.
91. Droste DW, Llull JB, Pezzoli C, Bogdahn U, Kaps M. SoonVue (BR1), a new long-acting echocontrast agent, improves transcranial colour-coded duplex ultrasonic imaging. Cerebrovasc Dis 2002; 14: 27-32.
92. Baumgartner RW, Mattle HP, Schroth G. Assessment of 50% and 50% intracranial stenosis by trans-cranial colour-coded duplex sonography. Stroke 1999; 30 (1): 87-92.
93. Kaps M, Seidel G, Bokor D, Modrau B, Algermissen C. Safety and ultrasound-enhancing potentials of a new sulfur hexafluoridecontaining agent in the cerebral circulation. J Neuroimaging 1999; 9: 150-154.
94. Baumgartner RW, Baumgartner I, Mattle HP, Schroth G. Transcranial colour-coded duplex sonography in the evaluation of collateral flow through the circle of Willis. AJNR Am J Neuroradiol 1997; 18 (1): 127-133.
95. Allendoerfer J, Goertler M, von Reutern GM. Prognostic relevance of ultra-early Doppler sonography in acute ischaemic stroke: A prospective multicentre study. Lancet Neurol 2006; 5 (10): 835-840.
96. Baracchini C, Manara R, Ermani M, Meneghetti G. The quest for early predictors of stroke evolution: Can TCD be a guiding light? Stroke 2000; 31 (12): 2942-2947.
97. Goertler M, Kross R, Baeumer M, Jost S, Grote R, Weber S, et al. Diagnostic impact and prognostic relevance of early contrastenhanced trans-cranial colour-coded duplex sonography in acute stroke. Stroke 1998; 29 (5): 955-962.
98. Toni D, Giorelli M, Bastianello S, Falcou A, Sette G, Ceschin V, et al. Acute ischemic strokes improving during the first 48 hours of onset: Predictability, outcome, and possible mechanism. A comparison with early deteriorating strokes. Stroke 1997; 28 (1): 10-14.
99. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351 (21): 2170-2178.
100. Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, Alvarez-Sabin J. Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke 2004; 35(1): 151-156.
101. Gerriets T, Postert T, Goertler M, Stolz E, Schlachetzki F, Silwka U, et al. DIAS I: duplex-sonographic assessment of the cerebrovascular status in acute stroke. A useful tool for future stroke trials. Stroke 2000; 31 (10): 2342-2345.
102. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282 (21): 2003-2011.
103. Leen E, Ceccotti P, Moug SJ, Glen P, MacQuarrie J, Angerson WJ, et al. Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatectomy for metastases: An essential investigation before resection? Ann Surg 2006; 243: 236-240.
104. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
105. Strobel D, Seitz K, Blank W, Schuler A, Dietrich C, Von Herbay A, et al. Contrast-enhanced ultrasound for the characterization of focal liver lesions-diagnostic accuracy in clinical practice (DEGUM multicenter trial). Ultraschall Med 2008; 29: 499-505.
106. Konopke R, Kersting S, Bergert H, Bloomenthal A, Gastmeier J, Saeger HD, et al. Contrast-enhanced ultrasonography to detect liver metastasis: A prospective trial to compare transcutaneous unenhanced and contrast-enhanced ultrasonography in patients undergoing laparotomy. Int J Colorectal Dis 2007; 22: 201-207.
107. Piscaglia F, Corradi F, Mancini M, Giangregorio F, Tamberi S, Ugolini G, et al. Real time contrast enhanced ultrasonography in detection of liver metastasis from gastrointestinal cancer. BMC Cancer 2007; 7: 171.
108. Nicolau C, Vilana R, Catalá V, Bianchi L, Gilabert R, García A, et al. Importance of evaluating all vascular phases on contrastenhanced sonography in the differentiation of benign from malignant focal liver lesions. Am J Roentgenol 2006; 186(1): 158-167.
109. Wilson SR, Burns PN. Microbubble contrast for radiological imaging. Applications. Ultrasound Q 2006; 2: 15-18.
110. Xu HX, Lu MD, Liu GJ, Xie XY, Xu ZF, Zheng YL, et al. Imaging of peripheral cholangiocarcinoma with low mechanical index contrast-enhanced sonography and SonoVue: Initial experience. J Ultrasound Med 2006; 25: 23-33.
111. Dietrich CF, Kratzer W, Strobe D, Danse E, Fessl R, Bunk A, et al. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 2006; 12: 1699-1705.
112. Bartolotta TV, Midiri M, Quaia E, Bertolotto M, Galia M, Cademartivi F, et al. Benign focal liver lesions: Spectrum of findings on SonoVue-enhanced pulse-inversion ultrasonography. Eur Radiol 2005; 15 (8): 1643-1649.
113. Quaia E, Calliada F, Bertolotto M, Rossi S, Garioni L, Rosa L, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: Diagnostic performance and confidence. Radiology 2004; 232: 420-430.
114. Wen YL, Kudo M, Zheng RQ, Ding H, Zhou P, Minami Y, et al. Characterization hepatic tumors: Value of contrast-enhanced coded phase-inversion harmonic angio. Am J Roentgenol 2004; 182: 1019-1026. (Erratum in: AJR Am J Roentgenol 2004; 1183(1014): 1175.
115. Albrecht T, Blomley MJK, Burns PN, Wilson S, Harvey CJ, Leen E, et al. Improved detection of hepatic metastasis with pulseinversion US during the liver-specific phase of SHU 508A: Multicentre study. Radiology 2003; 227: 361-370.
116. Quaia E, Bertolotto M, Calliada F, Mosconi E, Mucelli RP. US characterization of focal hepatic lesions with intermittent highacoustic-power mode and contrast media. Acad Radiol 2003; 10: 739-750.
117. Solbiati L, Martegani A, Leen E, Correas JM, Burns PN. Contrastenhanced ultrasound of liver disease. Milan: Spinger 2003.
118. Jang HJ, Lim HK, Lee WJ, Kim SH, Kim MJ, Choi D, et al. Focal hepatic lesions: Evaluation with contrast-enhanced gray-scale harmonic US. Korean J Radiol 2003; 4: 91-100.
119. Dill-Macky MJ, Burns PN, KahliliK, Wilson SR. Focal hepatic masses: Enhancement patterns with SH U 508A and pulseinversion US. Radiology 2002; 222: 95-102.
120. Beissert M, Jenett M, Keberle M, Keßler C, Klein D, Beer M, et al. Comparison of contrast harmonic imaging in B-mode with stimulated acoustic emission, conventional B-mode US and spiral CT in the detection of focal liver lesions. Fortschr Röntgenstr 2000; 172: 361-366.
121. Leen E, Angerson WJ, Yarmenitis S, Bongartz G, Blomley M, Del Maschio A, et al. Multi-centre clinical study evaluating the efficacy of SonoVue (BR1), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions. Eur J Radiol 2002; 41(3): 200-206.
122. Harvey C, Albrecht T. Ultrasound of focal liver lesions. Eur Radiol 2001; 11: 1578-1593.
123. Leen E. The role of contrast-enhanced ultrasound in the characterization of focal liver lesions. Eur Radiol 2001; 11(Suppl 3): E27-E34.
124. Tanaka S, Ioka T, Oshikawa O, Hamada Y, Yoshioka F. Dynamic sonography of hepatic tumors. Am J Roentgenol 2001; 177(4): 799-805.
125. Kim TK, Choi BI, Han JK, Hye-Suk H, Seong HP, Sung GM. Hepatic tumors: Contrast agent-enhancement patterns with pulseinversion harmonic US. Radiology 2000; 216: 411-417.
126. Wilson SR, Burns PN, Muradali D, Wilson JA, Lai X. Harmonic hepatic ultrasound with microbubble contrast agent: Initial experience showing improved characterization of haemangioma, hepatocellular carcinoma, and metastasis. Radiology 2000; 215: 153-161.
127. Tranquart F, Le Gouge A, Correas JM, Marcus VL, Manzoni P, Vilgrain V, et al. Role of contrast-enhanced ultrasound in the blinded assessment of focal liver lesions in comparison with MDCT and CEMRI: Results from a multicentre clinical trial. EJC 2008; 6: 9-15.
128. Catala V, Nicolau C, Vilana R, Pages M, Bianchi L, Sanchez M, et al. Characterization of focal liver lesions: Comparative study of contrast-enhanced ultrasound versus spiral computed tomography. Eur Radiol 2007; 17 (4): 1066-1073.
129. Hohmann J, Albrecht T, Hoffmann CW, Wolf KJ. Ultrasonographic detection of focal liver lesions: Increased sensitivity and specificity with microbubble contrast agents. Eur J Radiol 2003; 46: 147-159.
130. Harvey CJ, Blomley MJ, Eckersley RJ, Cosgrove DO, Patel N, Heckemann RA, et al. Hepatic malignancies: Improved detection with pulse-inversion US in late phase of enhancement with SH U508A-Early experience. Radiology 2000; 216: 903-908.
131. Torzilli G, Del Fabbro D, Palmisano A, Donadon M, Bianchi P, Roncalli M, et al. Contrast-enhanced intraoperative ultrasonography during hepatectomies for colorectal cancer liver metastases. J Gastrointest Surg 2005; 9: 1148-1153; discussion 1153-1144.
132. Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 2007; 33: 318-325.
133. Kono Y, Steinbach GC, Peterson T, Schmid-Schönbein GW, Mattrey RF. Mechanism of parenchymal enhancement of the liver with a microbubble-based US contrast medium: An interval microscopy study in rats. Radiology 2002; 224: 253-257.
134. Higgins H, Berger DL. RFA for liver tumors: Does it really work? Onclologist 2006; 11: 801-808.
135. Vilana R, Bianchi L, Varela M, Nicolau C, Sánchez M, Ayuso C. Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma? Eur Radiol 2006; 16(11): 2454-2462.
136. Kiaka Y, Hirooka M, Kumagi T, Uehara T, Hiasa Y, Kumano S, et al. Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation. Liver Int 2006; 26 (10): 1241-1247.
137. Dill-Macky MJ, Asch M, Burns P, Wilson S. Radiofrequency ablation of hepatocellular carcinoma: Predicting success using contrast-enhanced sonography. AJR Am J Roentgenol 2006; 186: S287-S295.
138. Raut CP, Izzo F, Marra P, Ellis LM, Vauthey J-N, Cremona F, et al. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol 2005; 12: 616-628.
139. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, et al. Percutaneous radiofrequency ablation from hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201-1209.
140. Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 1352-1360.
141. Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003; 90: 1240-1243.
142. Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS, et al. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology 2001; 220: 145-149.
143. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: Long-term results in 117 patients. Radiology 2001; 221: 159-166.
144. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, et al. Hepatocellular carcinoma: Radio-frequency ablation of medium and large lesions. Radiology 2000; 214: 761-768.
145. Solbiati L, Goldberg SN, Ierace T, Dellanoce M, Livraghi T, Gazelle GS. Radio-frequency ablation of hepatic metastases: Postprocedural assessment with a US microbubble contrast agent-early experience. Radiology 1999; 211(3): 643-649.
146. Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996; 167: 759-768.
147. Dill-Macky MJ, Asch M, Burns P, Wilson S. Original research. Radiofrequency ablation of hepatocellular carcinoma: predicting success using contrast-enhanced sonography. Am J Roentgenol 2005; 186: DOI: 10.2214/AJR.04.1916.
148. Solbiati L, Ierace T, Tonolini M, Cova L. Guidance and monitoring of radiofrequency liver tumor ablation with contrastenhanced ultrasound. Eur J Radiol 2004; 51S: 19-23.
149. Wen YL, Kudo M, Zheng RQ, Minami Y, Chung H, Suetomi Y, et al. Radiofrequency ablation of hepatocellular carcinoma: therapeutic response to using contrast-enhanced coded phaseinversion harmonic sonography. Am J Roentgenol 2003; 181: 57-63.
150. Meloni MF, Goldberg SN, Livraghi T. Hepatocellular carcinoma treated with radiofrequency ablation: Comparison of pulse inversion contrast-enhanced harmonic sonography and helical CT. Am J Roentgenol 2001; 177: 375-380.
151. Solbiati L, Goldberg SN, Ierace T, Livraghi T, Meloni F, Dellanoce M, et al. Hepatic metastases: percutaneous radiofrequency ablation with cooled-tip electrodes. Radiology 1997; 205(2): 367-373.
152. Solbiati L, Tonolini M, Lerace T. Guidelines of percutaneous tumor ablation. In: Lencioni R, Ed. Enhancing the role of ultrasound with contrast agents. Heildelberg: Springer 2006: 69-76.
153. Morimoto M, Nozawa A, Numata K, Shirato K, Sugimori K, Kokawa A, et al. Evaluation using contrast-enhanced harmonic gray scale sonography after radio frequency ablation of small hepatocellular carcinoma: Sonographic-histopathologic correlation. J Ultrasound Med 2005; 24: 273-283.
154. Minami Y, Kudo M, Kawasaki T, Chung H, Ogawa C, Shiozaki H, et al. Treatment of hepatocellular carcinoma with percutaneous radiofrequency ablation: Usefulness of contrast harmonic sonography for lesions poorly defined with B-mode sonography. AJR Am J Roentgenol 2004; 183: 153-156.
155. Choi D, Lim HK, Lee WJ, Kim SH, Kim YH, Kim SH, et al. Early assessment of the therapeutic response to radio frequency ablation for hepatocellular carcinoma: Utility of grey scale harmonic ultrasonography with a microbubble contrast agent. J Ultrasound Med 2003; 22: 1163-1172.
156. Cova L, Solbiati L, Lerace T. Usefulness of contrast-enhanced ultrasonography and real-time low mechanical index harmonic imaging in the selection and monitoring of patients undergoing percutaneous radiofrequency thermal ablation of liver tumors. Eur Radiol 2003; 13: S124.
157. Rhim H, Goldberg SN, Dodd GD, Solbiati L, Lim HK, Tonolini M, et al. Essential techniques for successful radio-frequency thermal ablation of malignant hepatic tumors. Radiographics 2001; 21(Suppl 1): S17-S35.
158. Cioni D, Lencioni R, Rossi S, Garbagnati F, Donati F, Crocetti L, et al. Radiofrequency thermal ablation of hepatocellular carcinoma: using contrast-enhanced harmonic power Doppler sonography to assess treatment outcome. AJR Am J Roentgenol 2001; 177: 783-788.
159. Rehman S, Jayson GC. Molecular imaging of antiangiogenic agents. Oncologist 2005; 10: 92-103.
160. De Giorgi U, Aliberti C, Benea G, Conti M, Marangolo M. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2005; 11: 6171-6176.
161. Lassau N, Lamuraglia M, Leclere J, Bidault S, Girard E. Functional and early evaluation of treatments in oncology: Interest of ultrasonographic contrast agents. J Radiol 2004; 85: 704-712.
162. Vogt FM, Antoch G, Veit P, Freudenberg LS, Blechschmid N, Diersch O, et al. Morphological and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: Comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT. J Nucl Med 2007; 48 (11): 1836-1844.
163. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
164. World Health Organization Offset Publication e. WHO Handbook for Reporting Results of Cancer Treatment Geneva, Switzerland 1979.
165. Lassau N, Lamuraglia M, Chami L, Leclère J, Bonvalot S, Terrier S, et al. Gastrointestinal stromal tumors treated with imatinib: Monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 2006; 187: 1267-1273.
166. Ota T, Ono S. Intrapancreatic accessory spleen: Diagnosis using contrast enhanced ultrasound. Br J Radiol 2004; 77: 148-149.
167. D'Onofrio M, Zamboni G, Falccioli N, Capelli P, Mucelli RP. Ultrasonography of the pancreas. 4. Contrast-enhanced imaging. Abdom Imaging 2007; 32: 171-181.
168. Hocke M, Schulze E, Gottschalk P, Topalidis T, Dietrich CF. Contrast-enhanced endoscopic ultrasound in discrimination between focal pancreatitis and pancreatic cancer. World J Gastroenterology 2006; 12: 246-250.
169. Masaki T, Ohkawa S, Amano A, Ueno M, Miyakawa K, Tarao K. Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma. Cancer 2005; 53: 854-859.
170. D'Onofrio M, Zamboni G, Malago R, Falconi M, Capelli P, Mansueto G. Pancreatic pathology. In: Quaia E (ed). Contrast media in ultrasonography. Berlin: Springer-Verlag 2005: 335-247.
171. D'Onofrio M, Mansueto G, Falconi M, Procacci C. Neuroendocrine pancreatic tumor: Value of contrast enhanced ultrasonography. Abdom Imaging 2004; 29: 246-258.
172. Flath B, Rickes S, Schweigert M, Lochs H, Possinger K, Wermke W. Differentiation of a pancreatic metastasis of a renal cell carcinoma from a primary pancreatic carcinoma by echo-enhanced power Doppler sonography. Pancreatology 2003; 3: 349-351.
173. Nagase M, Furuse J, Ishii H, Yoshino M. Evaluation of contrast enhancement patterns in pancreatic tumors by coded harmonic sonographic imaging with a microbubble contrast agent. J Ultrasound Med 2003; 22: 789-795.
174. Rickes S, Unkrodt K, Neye H, Ocran KW, Wermke W. Differentiation of pancreatic tumors by conventional ultrasound, unenhanced and echo-enhanced power Doppler sonography. Scand J Gastroenterol 2002; 37: 1313-1320.
175. Koito K, Namieno T, Nagakawa T, Morita K. Inflammatory pancreatic masses: Differentiation from ductal carcinomas with contrast-enhanced sonography using carbon dioxide microbubbles. Am J Roentgenol 1997; 169: 1263-1267.
176. Takeshima K, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Ichikawa H, et al. Comparison of IV contrast-enhanced sonography and histopathology of pancreatic cancer. Am J Roentgenol 2005; 185: 1193-1200.
177. Numata K, Ozawa Y, Kobayahi N, Kubota T, Shimada H, Nozawa A, et al. Contrast-enhanced sonography of pancreatic carcinoma: Correlations with pathological findings. J Gastroenterol 2005; 40: 631-640.
178. Schmidt T, Hohl C, Haage P, Blaum M, Honnef D, Weiß C, et al. Diagnostic accuracy of phase-inversion tissue harmonic imaging versus fundamental B-mode sonography in evaluation of focal lesions of the kidney. AJR Am J Roentgenol 2003; 180: 1639-1647.
179. Correas JM, Claudon M, Tranquart F, Hélénon O. Contrast enhanced ultrasonography: Renal applications. J Radiol 2003; 84: 2041-2054.
180. Claudon M, Plouin PF, Baxter GM, Rohban T, Devos DM. Renal arteries in patients at risk of renal arterial stenosis: Multicenter evaluation of the echo-enhancer SH U 508A at color and spectral Doppler US. Levovist Renal Artery Stenosis Study Group. Radiology 2000; 214: 739-746.
181. Wiijkstra H, Wink MH, de la Rosette JJ. Contrast specific imaging in the detection and localization of prostate cancer. World J Urol 2004; 22: 346-350.
182. Frauscher F, Klauser A, Halpern EJ, Horninger W, Bartsch G. Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet 2001; 357: 1849-1850.
183. Halpern EJ, Rosenberg M, Gornella LG. Prostate cancer: Contrastenhanced US for detection. Radiology 2001; 219: 219-225.
184. Blomley M, Kiely P, Harvey CJ, Cosgrove D. Microbubble contrast in transrectal biopsy. Lancet 2001; 358: 1643.
185. Laniado ME. Microbubble contrast in transrectal biopsy. Lancet 2001; 358: 1643.
186. Kiely P, Butler-Barnes J, Blomley MJK, et al. Transrectal biopsy of the prostate with infused microbubble contrast. Radiology 1998; 209: 1241.
187. Zdemir A, Kilic K, Ozdemir, H, Yucel C, Andac S, Colak M. Contrast-enhanced power Doppler sonography in breast lesions: Effect on differential diagnosis after mammography and gray scale sonography. J Ultrasound Med 2004; 23: 183-195.
188. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: A systematic review of the literature and meta-analysis. Cancer Res 2004; 64: 2941-2955.
189. Martinez AM, Medina CJ, Bustos C, Hernandez J. An assessment of breast lesions using Doppler with contrast agents. Eur J Gynaecol Oncol 2003; 24: 527-530.
190. Schroeder RJ, Bostanjoglo M, Rademaker J, Maeurer J, Felix R. Role of power Doppler techniques and ultrasound contrast enhancement in the differential diagnosis of focal breast lesions. Euro Radial 2003; 13 (1): 68-79.
191. Muradali M, Kulkarni S, Villet C, Burns PN, Kalman P, Wilson SR. Angiogenesis mapping with pulse inversion: A new and sensitive method to image vascularity in breast carcinomas. Radiology 2002; 225: 367.
192. Kedar PP, Cosgrove DO, McCready VR, Bamber JC, Carter EC. Microbubble contrast agent for color Doppler US: effect on breast masses. Radiology 1996; 198: 679-686.
193. Sever A, Jones S, Cox K, Weeks J, Mills P, Jones P. Preoperative localization of sentinel lymph nodes using intraderrmal microbubbles and contrast-enhanced ultrasonography in patients with breast cancer. Br J Surg 2009; 96: 1295-1299.
194. Goldfarb LR, Alazraki NP, Eshima D, Eshima LA, Herda SC, Halkar RK. Lymphoscintigraphic identification of sentinel lymph nodes: Clinical evaluation of 0.22-micron filtration of Tc-99m sulphur colloid. Radiology 1998; 208: 505-509.
195. Govaert GA, Oostenbroek RJ, Plaisier PW. Prolonged skin staining after intradermal use of patent blue in sentinel lymph node biopsy for breast cancer. Eur J Surg Oncol 2005; 31: 373-375.
196. Alvarez S, Anorbe E, Alcorta P, Lopez F, Alonso I, Cortes J. Role of sonography in diagnosis of axillary lymph node metastasis in breast cancer: A systematic review. AJR Am J Roentgenol 2006; 186: 1342-1348.
197. Goldberg BB, Merton DA, Liu JB, Thakur M, Murphy GF, Needleman L, et al. Sentinal lymph nodes in a swine model with melanoma: Contrast-enhanced lymphatic US. Radiology 2004; 230: 727-734.
198. Blomley M. Can microbubbles be targeted to lymph nodes? Radiology 2004; 231: 611-612.
199. Bude RO. Does contrast enhanced US have potential for sentinel lymph node detection? Radiology 2004; 230: 603-604.
200. Argalia G, De Bernardis S, Mariani D, Abbattista T, Taccaliti A, Ricciardelli L, et al. Ultrasonographic contrast agent: Evaluation of time-intensity curves in the characterization of solitary thyroid nodules. Radiol Med (Torino) 2002; 103: 407-413.
201. Rallan D, Harland CC. Ultrasound in dermatology. Basic principles and applications. Clin Exp Dermatol 2003; 28: 632-638.
202. Fleischer AC, Parsons AK, Cullinan JA. Contrast Enhanced Sonohysterography and Sonohysterosalpinography. In: Goldberg BG, Ed. Ultrasound Contrast Agents. London: Martin Dunitz 1997: 43-56.
203. Killam A, Dittrich HC. Cardiac Applications of Albunex and FS069. In: Goldberg BG, Ed. Ultrasound Contrast Agents. London: Martin Dunitz 1997: 43-56.
204. D'Arcy T, Jayaram V, Lynch M, Soutter W, Cosgrove D, Harvey C, et al. Ovarian cancer detected non-invasively by contrastenhanced power Doppler ultrasound. Br J Obstet Gynaecol 2004; 111 (6): 619-22.
205. Darge K. Contrast-enhanced voiding urosonography for diagnosis of vesicoureteral reflux in children. Pediatr Radiol 2007; 38: 40-63.
206. Papadopoulou F, Katzioti F, Arkoumani E, Siomou E, Efremidis S, Tsamboulas C, et al. Voiding urosonography harmonic imaging with 2nd generation contrast agent for the diagnosis of reflux. Pediatr Radiol 2005; 35: S31.
207. Bosio M, Xhepa R, Pandolfi M. Advancements in the diagnosis of vesico-ureteral reflux with cystourethrosonography (CUS): A comparative study between 1st and 2nd generation contrast media. Pediatr Nephrol 2005; 20: C95.
208. Darge K, Beer M, Gordjani N, Riedmiller H. Contrast-enhanced voiding urosonography with the use of a 2nd generation US contrast medium: preliminary results. Pediar Radiol 2004; 34: S97.
209. Ascenti G, Zimbaro G, Mazziotti S, Roberto C, Carmelo F, Carmela V, et al. Harmonic US imaging of vesicoureteric reflux in children: Usefulness of a second generation US contrast agent. Pediatr Radiol 2004; 34: 481-487.
210. Berrocal T, Gaya F, Arjonilla A, Lonergan GJ. Vesicoureteral reflux: Diagnosis and grading with echo-enhanced cystosonography versus voiding cystourethography. Radiology 2001; 221: 359-365.
211. Darge K, Troegar J, Duetting T, Zieger BMD, Wiltrud Rohrschneider MD, Moehring K, et al. reflux in young patients: Comparison of voiding US of the bladder and retrovesical space with echo enhancement versus voiding cystourethrography for diagnosis. Radiology 1999; 210: 201-207.
212. Riccabona M. Cystography in infants and children: A critical appraisal of the many forms with special regard to voiding cystourethrography. Eur Radiol 2002; 12: 2910-2918.
213. Kenda RB. Imaging techniques for the detection of vesicoureteric reflux: What and when? Nephrol Dial Transplant 2001; 16: 4-7.
214. Darge K, Ghods S, Zieger B, Rohrschneider W, Troeger J. Reduction in voiding cystourethrographies after the introduction of contrast enhanced sonographic reflux diagnosis. Pediatr Radiol 2001; 31: 790-795.
215. Vassiou K, Vlychou M, Moisidou R, Sioka A, Fezoulidis IV. Contrast-enhanced sonography in detection of vesicoureteral reflux in children: Comparison with voiding cystourethrography. Röntgensrt Fortschr 2004; 176: 1453-1457.
216. Galloy MA, Mandry D, Pecastaings M, Mainard-Simard L, Claudon M. Sonocystography: A new method for the diagnosis and follow-up of vesico-ureteric reflux in children. J Radiol 2003; 84: 2055-2061.
217. Uhl M, Kromeier J, Zimmerhackl LB, Darge K. Simultaneous voiding cystourethrography and voiding urosonography. Acta Radiol 2003; 44: 265-268.
218. Valentini AL, De Gaetano AM, Destito C, Marino V, Minordi LM, Marano P. The accuracy of voiding urosonography in detecting vesico-ureteral reflux: A summary of existing data. Eur J Pediatr 2002; 161: 380-384.
219. Radmayr C, Klauser A, Pallwein L, Zurnedden D, Bartsch G, Frauscher F. Contrast enhanced reflux sonography in children: A comparison to standard radiological imaging. J Urol 2002; 167: 1428-1430.
220. Kenda RB, Novljan G, Kenig A, Hojker S, Fettich JJ. Echoenhanced ultrasound voiding cystography in children: A new approach. Pediatr Nephrol 2000; 14: 297-300.
221. Mentzel HJ, Vogt S, Patzer L, Schubert R, John U, Misselwitz J, et al. Contrast-enhanced sonography of vesicoureterorenal reflux in children: Preliminary results. AJR Am J Roentgenol 1999; 173: 737-740.
222. Bosio M. Cystosonography with echocontrast: A new imaging modality to detect vesicoureteric reflux in children. Pediatr Radiol 1998; 28: 250-255.
223. Correas J, Helenon O, Moreau JF. Contrast-enhanced ultrasonography of native and transplanted kidney diseases. Eur Radiol 1999; 9 (Suppl 3): S394-400.
224. Schmiedl UP, Carter S, Martin RW, Eubank W, Winter T, Chang PP, et al. Sonographic detection of acute parenchymal injury in an experimental porcine model of renal hemorrhage: Grey-scale imaging using a sonographic contrast agent. AJR Am J Roentgenol 1999; 173: 1289-1294.
225. de Zordo T, Mlekusch SP, Feuchtner GM, Mur E, Schirmer M, Klauser AS. Value of contrast-enhanced ultrasound in rheumatoid arthritis. Eur J Radiol 2007; 64: 222-230.
226. Rees JD, Pilcher J, Heron C, Kiely PD. A comparison of clinical vs ultrasound determined synovitis in rheumatoid arthritis utilizing grey-scale power Doppler and the intravenous microbubble contrast agent "Sono-Vue". Rheumatology (Oxford) 2007; 46 (3): 454-459.
227. Kaiser A. Value of Contrast-Enhanced Ultrasound in Rheumatoid Arthritis. In: Ricardo L, Ed. Enhancing the Role of Ultrasound with Contrast Agents. Heidelberg: Springer 2006; 239-252.
228. Klauser A, Demharter J, De Marchi A, Sureda D, Barile A, Masciocchi C, et al. The IACUS study group. Contrast enhanced gray-scale sonography in assessment of joint vascularity in rheumatoid arthritis: Results from the IACUS study group. Euro Radial 2005; 15 (12): 2404-2410.
229. Klauser A, Halpern EJ, Frauscher F, Gvozdic D, Duftner C, Springer P, et al. Inflammatory low back pain: High negative predictive value of contrast-enhanced color Doppler ultrasound in the detection of inflamed sacroiliac joints. Arthritis Rheum 2005; 53 (3): 440-444.
230. Wamser G, Bohndorf K, Vollert K, Bucklein W, Schalm J. Power Doppler sonography with and without echo-enhancing contrast agent and contrast-enhanced MRI for the evaluation of rheumatoid arthritis of the shoulder joint: Differentiation between synovitis and joint effusion. Skeletal Radial 2003; 32(6): 351-359.
231. Carotti M, Salaffi F, Manganelli P, Salera D, Simonetti B, Grassi W. Power Doppler sonography in the assessment of synovial tissue of the knee joint in rheumatoid arthritis: A preliminary experience. Ann Rheum Dis 2002; 61 (10): 877-882.
232. Klauser A, Frauscher F, Schirmer M, Halpern E, Pallwein L, Herold M, et al. The value of contrast-enhanced color Doppler ultrasound in the detection of vascularization of finger joints in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46 (3): 647-653.
233. Blomley MJ, Cooke JC, Unger EC, Monaghan MJ, Cosgrove DO. Microbubble contrast agents: A new era in ultrasound. BMJ 2001; 322 (7296): 1222-1225.
234. Taylor PC. Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology (Oxford) 2005; 44(6): 721-728.
235. Bodolay E, Koch AE, Kim J, Szegedi G, Szegedi G, Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 2002; 6 (3): 357-367.
236. Backhaus M, Kamradt T, Sandrock D, Loreck D, Fritz J, Wolf KJ, et al. Arthitis of the finger joints: A comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum 1999; 42 (6): 1232-1245.
237. Koch AE. Review: angiogenesis: Implications for rheumatoid arthritis. Arthritis Rheum 1998; 41 (6): 951-962.
238. Tinkov S, Coester C, Serba S, Geis NA, Katus HA, Winter G, et al. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: In vivo characterization. J Control Release 2010 [Epub ahead of print]
239. Klibanov AL. Ligand-carrying gas-filled microbubbles: Ultrasound contrast agents for targeted molecular imaging. Bioconjug Chem 2005; 16: 9-17.
240. Tsutsui JM, Xie F, Porter RT. The use of microbubbles to target drug delivery. Cardiovasc Ultrasound 2004; 2: 23.
241. Tsutsui JM, Grayburn PA, Xie F, Porter TR. Drug and gene delivery and enhancement of thrombolysis using ultrasound and microbubbles. Cardiol Clin 2004; 22(2): 299-312.
242. Klibanov AL. Targeted delivery of gas-filled microspheres, contrast agents for ultrasound imaging. Adv Drug Deliv Rev 1999; 37: 139-157.
243. Hosseinkhani H, Aoyama T, Ogawa O, Tabata Y. Ultrasound enhances the transfection of plasmid DNA by non-viral vectors. Curr Pharm Biotechnol 2003; 4: 109-122.
244. Anwer K, Kao G, Proctor B, Anscombe I, Florack V, Earls R, et al. Ultrasound enhancement of cationic lipid-mediated gene transfer to primary tumors following systemic administration. Gene Ther 2000; 7: 1833-1839.
245. Huber PE, Pfister P. In vitro and in vivo transfection of plasmid DNA in the dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther 2000; 7: 1516-125.
246. Miller DL, Bao S, Gres RA, Thrall BD. Ultrasonic enhancement of gene transfection in murine melanoma tumors. Ultrasound Med Biol 1999; 25: 1425-1430.
247. Mukherjee D, Wong J, Griffin B, Ellis SG, Porter T, Sen S, et al. Ten-fold augmentation of endothelial uptake of vascular endothelial growth factor with ultrasound after systemic administration. J Am Coll Cardiol 2000; 35: 1678-1686.
248. Zderic V, Vaezy S, Martin RW, Clark JI. Ocular drug delivery using 20kHz ultrasound. Ultrasound Med Biol 2002; 28: 823-829.
249. Juffermans L, Dijkmans PA, Musters RJ, Visser CA, Kamp O. Transient permeabilization of cell membranes by ultrasoundexposed microbubbles is related to formation of hydrogen peroxide. Am J Physiol Heart Circ Physiol 2006; 291: 1595-1601.
250. Marmottant P, Hilgenfeldt S, Versluis M, Gardeniers H, van den Berg A, Lohse D. Cell permeabilisation and transport focused around oscillating microbubbles. Proceedings of the XXI International Congress of Theoretical and Applied Mechanics Poland: Warsaw 2004.
251. Wei W, Zheng-Zhong B, Yong-Jie W, Qing-Wu Z, Ya-Lin M. Bioeffects of low-frequency ultrasonic gene delivery and safety on cell membrane permeability control. J Ultrasound Med 2004; 23: 1569-1582.
252. Guzman HR, McNamara AJ, Nguyen DX, Prausnitz MR. Bioeffects caused by changes in acoustic cavitation bubble density and cell concentration: A unified explanation based on cell-tobubble ratio and blast radius. Ultrasound Med Biol 2003; 29: 1211-1222.
253. Marmottant P, Hilgenfeldt S. Controlled vesicle deformation and lysis by single oscillating bubbles. Nature 2003; 423: 152-156.
254. Miller DL, Pislaru SV, Greenleaf JF. Sonoporation: Mechanical DNA delivery by ultrasonic cavitation. Som Cell Mol Genet 2002; 27: 115-134.
255. Miller DL, Quddus J. Sonoporation of monolayer cells by diagnostic ultrasound activation of contrast-agent gas bodies. Ultrasound Med Biol 2000; 26: 661-667.
256. Wang ZQ, Pecha R, Gompf B, Eisenmenger W. Single bubble sonoluminescence: Investigations of the emitted pressure wave with a fiber-optic probe hydrophone. Phys Rev E 1999; 59: 1777-1780.
257. Barnett S. Nonthermal issues: Cavitation- Its nature, detection and measurement. Ultrasound Med Biol 1998; 24: 152-156.
258. Miller DL, Thomas RM. A comparison of hemolytic and sonochemical activity of ultrasonic cavitation in a rotating tube. Ultrasound Med Biol 1993; 19: 83-90.
259. Dai, Z., Ke, H., Xing, Z., Yue, X., Wang, J., Liu, J. Microcapsular ultrasound contrast agent based on surfactant and preparation method thereof. CN11406706 (2009).
260. Lin, L., Cai, M., Chen, Z., Xue, E. Novel PLGA-PEG-PLGA multipolymer microbubble ultrasound contrast agent and preparation method thereof. CN11574530 (2009).
261. Ostensen, J., Frigstad, S., Eriksen, M., Rongved, P. Improvements in or relating to contrast agents. EP1264604 (2007).
262. Azuma, T., Kawabata, K. Ultrasonic imaging apparatus. EP1965224 (2010).
263. Azuma, T., Umemura, S. Ultrasonic imaging apparatus. US20100099986 (2010).
264. Itani, K. Ultrasound diagnostic apparatus for nonlinear contrast imaging. EP2154548 (2010).
265. Kruecker, J., Xu, S., Jiang, H. Interventional navigation using 3D contrast-enhanced ultrasound. WO2009063423 (2009).
266. Sengupta, P.P., Belohlavek, M., Khandheria, B.K. Method for imaging intracavitary blood flow patterns. US20090187100 (2009).
267. Wang, Y. Tracer kinetic models for acoustic contrast imaging applications using photo-acoustics or thermo-acoustics. WO2009057019 (2009).
268. Naghavi, M., Kakadiaris, I.A. Methods and apparatuses for medical imaging. US20080281205 (2008).
269. Schutt, E.G. Harmonic ultrasound imaging with microbubbles. US7374744 (2008).
270. Allemann, E., Bettinger, T., Bussat, P., Hauwel, M., Yan, F. Standalone umbrella. WO201004072 (2010).
271. Jolesz, F.A., Fischer, K., McDannold, N. Method for modifying glomerular permeability and function with focused ultrasound. WO2010022239 (2010).
272. Conston, S.R., Yamamoto, R., Ottoboni, T.B., Tickner, E.G. Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility. US20090297567 (2009).
273. Hossack, J.A., Wamhoff, B.R., Klibanov, A.L. System for treatment and imaging using ultrasonic energy and microbubbles and related method thereof. WO2009055720 (2009).
274. Mattrey, R., Simberg, D. Use of gas-filled microbubbles for selective partitioning of cell populations and molecules in vitro and in vivo. WO2009052057 (2009).
275. Rapoport, N., Gao, Z. Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents. US20090117177 (2009).
276. Burns, P.N., Karshafian, R., Czarnota, G. Method and system of radiotherapy enhancement through cellular perturbation using ultrasound and microbubbles. WO2008110001 (2008).
277. Karshafian, R., Czarnota, G., Burns, P.N. Method and system of radiotherapy enhancement through cellular perturbation using ultrasound and microbubbles. US20080221382 (2008).
278. Lai, K., Lan, H. Ultrasound microbubble mediated genes delivery system. WO2008058451 (2008).
279. Lindner, J.R., Kaufmann, B., McCarty, O.J.T. Ultrasound imaging with targeted microbubbles. WO2008131217 (2008).